Navigation Links
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
Date:7/21/2008

September meeting to focus on use of Zevalin as consolidation therapy after

remission induction in previously untreated patients with follicular

lymphoma

SEATTLE, July 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Company has scheduled a meeting with the U.S. Food and Drug Administration (FDA) in September to discuss the possibility of filing a supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. The basis for the filing would be data from the First-line Indolent Trial that CTI recently gained access to through an agreement with Bayer Schering Pharma.

"We are pleased to have scheduled a meeting with the FDA to discuss a label expansion for Zevalin which could broaden its availability to patients," said James A. Bianco, M.D., President and CEO of Cell Therapeutics. "We continue to make progress with Zevalin on multiple fronts with clarity on reimbursement rates, deployment of our national sales team and now the opportunity to meet with the FDA to discuss possibly expanding the label for Zevalin."

About the Phase III First-line Indolent (FIT) Trial

The multinational, randomized phase III First-line Indolent Trial (FIT) evaluated the benefit and safety of a single infusion of Zevalin in patients with CD20-positive follicular non-Hodgkin's lymphoma who had achieved a partial response or a complete response after receiving standard first-line chemotherapy regimens. The FIT trial results were presented in one oral and two poster presentations at the American Society of Hematology (ASH) conference in December 2007. The FIT trial demonstrated that when used as a first-line consolidation therapy for patients with follicular non-Hodgkin's lymphoma, Zevalin significantly impro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
5. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
6. APIC Conference to Discuss MRSA Elimination
7. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
8. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
9. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Conn. , July 31, 2014  UBM Medica ... a leading online community for oncologists, presents exclusive slide ... that are essential to quality cancer care. ... journal ONCOLOGY , offers news, blogs, and podcasts ... for oncologists highlighting quality cancer care: , End-of-life ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group is ... intelligence product Marketrack to now include ChinaTrack; the new ... landscape in an interactive dashboard providing detailed brand-level share ... at a hospital level. Other key capabilities ... data feed: In addition to end-user surveys of healthcare ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Lazarus Effect Closes $5 Million Financing 2
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx,Incorporated ... its,randomized, blinded, placebo-controlled phase 2 clinical trials ... rheumatoid,arthritis (RA) will be featured at the ... Rheumatology meeting, June,13-16, 2007 in Barcelona, Spain., ...
... study results confused the public about the,need and ... /PRNewswire/ -- The onslaught of,anti-stent news reports over ... that angioplasty doesn't work and its use should,decrease. ... their cardiologists about the benefits of stenting. , ...
Cached Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3To Stent or Not: Is That the Question? 2
(Date:8/1/2014)... (PRWEB) August 01, 2014 Register to join ... of the most active years on record for life sciences ... life sciences represented 22 percent of all venture dollars spent ... and achieved high valuations. , However, 2014 is proving ... recent report by Silicon Valley Bank, while life sciences IPOs ...
(Date:7/31/2014)... HEIGHTS, Ill. (August 1, 2014) Women over the ... an increased risk for obesity, greater struggles against poverty ... An article published in the August issue of ... publication of the American College of Allergy, Asthma and ... in treating asthma, and offers practical solutions to improve ...
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Ce-Classes.com has ... education course for healthcare professionals, a Systematic Review ... upon material published in the International Journal of Clinical ... created in response to a need to have accurate ... provide the best treatment possible. The material provides ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... (non-steroidal anti- inflammatory drug) treatment that can be applied directly to site of ... osteoarthritis pain * Voltaren Gel ... knees and the joints ... of the hands * Offers highly effective pain relief with ...
... Adopts InterviewDirect to ... Positions, CHERRY HILL, N.J., Oct. 22 ... telephone-based job candidate screening solutions,today announced that ... InterviewDirect service to pre-qualify job candidates for ...
... Science,Applications International Corporation (NYSE: SAI ) ... University of Kent on behalf of the United,Kingdom ... projects. Fostered by efforts of the UK ... cooperation from academia, industry and government in,collaborative research ...
... (Oct. 22, 2007)Work done in part by researchers at ... led to the discovery of two genes that cause ... The findings are published in the Oct. 21 online ... on the genetic basis for common and complex diseases. ...
... elderly patients with lung cancer has changed little despite ... The study by Harvard University, National Cancer Institute, and ... December 1, 2007 issue of CANCER, a peer-reviewed journal ... rose by less than one month between 1983 and ...
... other injuries at bay, experts say , , SUNDAY, Oct. 21 ... that Halloween is a treat for both children and adults, ... organization based in Chicago. , "We can keep Halloween safe ... Garrett, the group,s senior vice president, said in a prepared ...
Cached Medicine News:Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 2Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 3Health News:SAIC to Collaborate with UK Biometrics Institute 2Health News:SAIC to Collaborate with UK Biometrics Institute 3Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 2Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 3Health News:Spending more for lung cancer treatment did not substantially increase patients' lives 2Health News:Eye on Safety Makes Halloween Less Scary 2
... WH, the latest in the Magnes line of ... and its full cortical coverage, provides the highest ... allowing study of a wide range of neuronal ... choice of detector configurations and can be equipped ...
... a non-invasive and painless method of stimulating ... Laboratories manufactures two magnetic stimulation devices, the ... (HSMS). The Hight Speed MES-10 ... up to 25 Hz at full power. ...
... MOBEE headboxes are the ... line of portable battery-powered ... a robust new mechanical ... software, XLTEK's standard MOBEE24plus ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: